Biomedivir for the prophylaxis and treatment of Covid-19

Biomed Pharmaceuticals, Inc. was involved in the development of new anti-malarial drugs dated back in 1990s. During that time, there were more 100 million cases of malaria and 1 million people mostly children died in Africa and Asia.

The company developed a new drug, which was a derivative of Artemisinin under a brand name called ArteMed. ArteMed is an effective drug to treat Plasmodium falciparum malaria, that are resistant to chloroquine, which was the standard treatment for malaria at the time. The company formed a joint venture with a manufacturing company of pharmaceutical active ingredients in China in 1995.

Biomed formed a research collaboration with Walter Reed Army Research Institute in the USA (1995-1999) to further the development of new anti-malarial drugs. The company collaborated with World Health Organization (WHO) to coordinate clinical trials of ArteMed.

It has been shown that ArteMed is more efficacious and safer than chloroquine or hydroxychloroquine in treating malaria. (Ref: Clinical Infectious Diseases® 2018;66(2):229–36).

ArteMed has been approved as the last defense drug against chloroquine resistant Plasmodium falciparum malaria in more than 80 countries, include the FDA in the USA.

Biomed has developed Biomedivir™, which is comprised of two FDA approved drugs : ArteMed and an antiviral drug for the prophylaxis and treatment of Covid-19.

Biomed plans to conduct Phase 3 trials of Biomedivir™ for the prophylaxis and treatment of Covid-19 at various sites in the US and overseas.

Note: Biomedivir is in clinical trials and is not available for marketing in the USA at this time, unless it is approved by the FDA. Biomedivir is required physician's prescription. Patients should consult with physicians about the drug.

For further information, please contact us by completing an Online Contact Form. Thank you.